Arcellx (ACLX) Competitors $80.42 -1.61 (-1.96%) (As of 10:03 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACLX vs. BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, PCVX, and QGENShould you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Arcellx vs. BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen BeiGene (NASDAQ:BGNE) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability. Does the MarketBeat Community believe in BGNE or ACLX? BeiGene received 479 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 69.24% of users gave BeiGene an outperform vote. CompanyUnderperformOutperformBeiGeneOutperform Votes54769.24% Underperform Votes24330.76% ArcellxOutperform Votes6882.93% Underperform Votes1417.07% Is BGNE or ACLX more profitable? Arcellx's return on equity of -8.28% beat BeiGene's return on equity.Company Net Margins Return on Equity Return on Assets BeiGene-25.94% -25.12% -14.95% Arcellx -25.94%-8.28%-5.21% Do analysts prefer BGNE or ACLX? BeiGene currently has a consensus target price of $253.69, suggesting a potential upside of 41.68%. Arcellx has a consensus target price of $105.93, suggesting a potential upside of 29.14%. Given BeiGene's higher probable upside, research analysts clearly believe BeiGene is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeiGene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13 Does the media favor BGNE or ACLX? In the previous week, BeiGene had 1 more articles in the media than Arcellx. MarketBeat recorded 12 mentions for BeiGene and 11 mentions for Arcellx. Arcellx's average media sentiment score of 0.78 beat BeiGene's score of 0.49 indicating that Arcellx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeiGene 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcellx 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in BGNE or ACLX? 48.5% of BeiGene shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 7.4% of BeiGene shares are held by company insiders. Comparatively, 6.2% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, BGNE or ACLX? BeiGene has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Which has preferable valuation & earnings, BGNE or ACLX? Arcellx has lower revenue, but higher earnings than BeiGene. Arcellx is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeiGene$3.32B5.26-$881.71M-$8.24-21.73Arcellx$155.82M28.47-$70.69M-$0.71-115.53 SummaryArcellx beats BeiGene on 11 of the 18 factors compared between the two stocks. Ad Wall Street StarHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the Get Arcellx News Delivered to You Automatically Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACLX vs. The Competition Export to ExcelMetricArcellxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.44B$2.98B$5.19B$9.32BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-115.5346.24128.2217.54Price / Sales28.47420.891,259.00139.66Price / CashN/A182.1341.2237.95Price / Book8.233.924.884.92Net Income-$70.69M-$42.03M$119.69M$225.78M7 Day Performance-5.70%-3.37%16.64%-1.56%1 Month Performance-7.02%7.95%16.32%6.68%1 Year Performance64.91%21.00%35.37%22.48% Arcellx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACLXArcellx3.2007 of 5 stars$80.42-2.0%$105.93+31.7%+60.5%$4.35B$155.82M-113.27130BGNEBeiGene2.6509 of 5 stars$176.52-1.6%$253.69+43.7%-2.2%$17.20B$2.46B-21.7710,600MRNAModerna4.4064 of 5 stars$41.59-0.6%$79.50+91.2%-52.6%$16.00B$5.06B-7.195,600Analyst DowngradeVTRSViatris1.4235 of 5 stars$12.71+0.6%$13.67+7.5%+22.6%$15.17B$15.05B-17.0738,000SMMTSummit Therapeutics3.3861 of 5 stars$18.71+4.9%$33.33+78.2%+625.4%$13.80B$700,000.00-63.68105GMABGenmab A/S4.2563 of 5 stars$20.14-0.1%$45.20+124.4%-35.1%$13.33B$19.84B19.582,204Short Interest ↓Gap UpHigh Trading VolumeRDYDr. Reddy's Laboratories2.1282 of 5 stars$14.75+2.0%$17.00+15.3%+8.6%$12.31B$299.87B22.9527,048Positive NewsSRPTSarepta Therapeutics4.9049 of 5 stars$126.12+1.9%$178.71+41.7%+35.2%$12.05B$1.64B98.971,314Insider TradePositive NewsCTLTCatalent2.7772 of 5 stars$63.48+0.7%$63.40-0.1%+53.0%$11.52B$4.38B-27.9116,900Trading HaltedHigh Trading VolumePCVXVaxcyte1.8076 of 5 stars$90.59+3.3%$147.50+62.8%+48.4%$11.29BN/A-19.07160QGENQiagen4.2311 of 5 stars$45.41+0.0%$51.15+12.6%+3.6%$10.36B$1.97B117.035,967 Related Companies and Tools Related Companies BGNE Competitors MRNA Competitors VTRS Competitors SMMT Competitors GMAB Competitors RDY Competitors SRPT Competitors CTLT Competitors PCVX Competitors QGEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACLX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACLX Stock Alerts